MoonLake Immunotherapeutics (MLTX) Q3 2024 earnings summary

Executive summary

• Ended Q3 2024 with $493.9 million in cash, cash equivalents, and short-term marketable securities, supporting operations through 2026.

• Clinical-stage biotech focused on sonelokimab (SLK) for inflammatory skin and joint diseases, with no commercial products or revenue.

• Advanced SLK into Phase 3 trials for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA), with additional Phase 2/3 trials planned in PPP, axSpA, and adolescent HS.

• Positive regulatory feedback from FDA and EMA supports Phase 3 programs in HS and PsA.

• Sonelokimab demonstrated high clinical response rates and favorable safety in Phase 2 and 3 trials for HS and PsA.

Financial highlights

• Research and development expenses rose to $35.7 million for Q3 2024 (up 371% year-over-year) and $72.4 million for the nine months (up 205%).

• General and administrative expenses increased to $7.4 million for Q3 2024 (up 37%) and $21.1 million for the nine months (up 37%).

• Net loss for Q3 2024 was $36.1 million, and $74.8 million for the nine months ended September 30, 2024.

• Operating loss was $43.1 million for Q3 2024 and $93.5 million for the nine months.

• Other income, net, was $7.1 million for Q3 2024 and $18.9 million for the nine months, mainly from interest income.

Outlook and guidance

• Cash runway expected to last through the end of 2026, supporting ongoing and planned clinical programs.

• Anticipates continued significant R&D and operating losses as SLK advances through clinical development and pre-commercialization.

• Additional capital will be required for commercialization and further development beyond current pipeline.

• Anticipated primary endpoint readout for Phase 3 VELA program in HS by mid-2025.

• Enrollment for Phase 3 PsA trials (IZAR-1 and IZAR-2) to commence imminently.